There is the potential for it to be worth $125 a share or more, as has been pointed out before Gillead paid $11 billion for a hepatitis focused biotech in 2011. If we cure hcv and nsc lung cancer starts looking good then $100 will look cheap, if the technology platform we have is the real deal then I think even the wildest predictions might be conservative given how many things it could be applied to.
There is the potential for it to be worth $125 a share or more,...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)